Profitable Diagnostic Lab Investment Opportunity in Wilmington, USA

Business is in the pre-commercial stage and is developing its flagship product: a compact, AI-powered diagnostic device that uses radio frequency signals to rapidly detect pathogens in liquid samples. Once commercialized, this device will primarily be used by healthcare professionals, diagnostic laboratories, and point-of-care facilities for fast, non-invasive pathogen detection, improving early diagnosis and treatment decision-making. Future service offerings may include data analytics for disease monitoring and cloud-based AI enhancements to optimize diagnostic accuracy. Tangible assets.
1) Prototypes & lab equipment.
AI-powered diagnostic device prototypes.
RF signal analyzers and calibration tools.
Biosample preparation and handling equipment.
Computing hardware for AI model training.
2) Cloud & data infrastructure.
USD 350K in Google Cloud credits for AI processing and storage.
High-performance computing (HPC) access through Nvidia inception program.
3) Cash & grants.
USD 70K in non-dilutive grants received.
Expected USD 305K SBIR grant (pending approval).
USD 105K in SAFE investments raised.
4) Office & research facility access (via NorDx Partnership)
Use of NorDx’s 40,000 sq. ft. clinical laboratory infrastructure for validation and clinical testing. Facility & infrastructure – Powered by NorDx.
Business leverages the state-of-the-art infrastructure of NorDx, a leading CLIA/CAP-accredited clinical laboratory with a 40,000 sq. ft. facility in Scarborough, Maine. This collaboration allows us to conduct cutting-edge research, clinical validation, and product refinement within a high-throughput, real-world diagnostic environment.
Facility overview & access.
Built-Up Area: NorDx operates within a 40,000 sq. ft. facility, providing extensive laboratory space for advanced diagnostics.
Workforce & operational capacity: NorDx employs 630+ staff members and supports over 600 clients across Maine and New Hampshire.
High-volume testing: Processes 5+ million specimens annually, with 97% tested locally, ensuring rapid turnaround and robust infrastructure.
Key infrastructure & resources.
Clinical lab access: Business benefits from direct access to NorDx’s advanced laboratory services, allowing for seamless integration of our diagnostic technology into existing workflows.
High-end testing equipment:
RF signal analyzers for calibrating and validating AI-powered pathogen detection.
Biosafety level-compliant environments for handling biological samples.
Advanced clinical and molecular testing platforms for comparative analysis.
Pathology & data integration:
Collaboration with Spectrum Healthcare Partners for pathology expertise.
120+ client EMR interfaces across 21 distinct EMR systems, enabling data-driven insights and future interoperability with hospital networks.
Logistics & sample collection:
Contracted courier service with 34 drivers managing 54 routes, ensuring efficient specimen collection and distribution. Current funding & ownership structure.
The business is funded through a combination of founder investment, non-dilutive grants, cloud credits, and early-stage equity investments:
Founder investment:
USD 350K personally Founder & CEO to support early development, research, and operational needs.
Grants & credits:
USD 70K in non-dilutive grants already received.
USD 350K in Google Cloud credits to support AI and data processing infrastructure.
Expected USD 305K SBIR grant from NSF, currently in the pipeline.
Equity investments:
USD 105K raised through 3 SAFE notes from early investors.
Actively raising USD3M to accelerate commercialization and market entry.
Debt & loan status.
No outstanding loans or debts as of now, has prioritized non-dilutive and early-stage equity funding to maintain financial flexibility.
Ownership & shareholding structure.
Total number of shareholders: Currently, the company is privately held, with founder ownership and early investors via SAFE notes.
Equity breakdown:
Founder & CEO – Majority ownership, reflecting his USD 350K personal investment.
SAFE investors – Have future equity rights but do not yet hold a fixed percentage of ownership.
As the business progresses toward commercialization, the USD 3M fundraising round will further define equity allocations, with SAFE notes converting in future funding rounds. The company remains strategically positioned for growth, leveraging a mix of founder-backed capital, non-dilutive funding, and investor interest to scale operations and bring its AI-powered diagnostic technology to market.